A tropomyosin receptor kinase family protein, NTRK2 is a potential predictive biomarker for lung adenocarcinoma.
Xiang WangZhijie XuXi ChenXinxin RenJie WeiShuyi ZhouXue YangShuangshuang ZengLong QianGeting WuZhicheng GongYuanliang YanPublished in: PeerJ (2019)
Neurotrophic receptor tyrosine kinase 2 (NTRK2) is a member of the tropomyosin receptor kinase family associated with the tumor development. However, the detailed function of NTRK2 in lung cancer, especially in lung adenocarcinoma (LUAD), is still not fully understood. Here, we investigated the effects of NTRK2 on LUAD biology. Through analyzing bioinformatics data derived from several databases, such as Oncomine, Gene Expression Profiling Interactive Analysis and UALCAN, we found that NTRK2 expression was significantly decreased in LUAD tissues. Clinical data acquired from Wanderer database, which is linked to The Cancer Genome Atlas database, demonstrated that the expression and methylation site of NTRK2 were significantly related to the clinical characteristics and prognosis of LUAD. Furthermore, NTRK2 expression was increased remarkably after treatment with the protein kinase B (AKT) inhibitor MK2206 and the anticancer agent actinomycin D. Functional enrichment analysis of NTRK2-associated coexpression genes was further conducted. Together, our results suggested that downregulated NTRK2 might be used in the diagnostic and prognostic evaluation of LUAD patients, or as a potential therapeutic target for the treatment of LUAD.
Keyphrases
- tyrosine kinase
- genome wide
- poor prognosis
- protein kinase
- binding protein
- gene expression
- big data
- dna methylation
- epidermal growth factor receptor
- electronic health record
- newly diagnosed
- cell proliferation
- emergency department
- machine learning
- genome wide identification
- transcription factor
- adverse drug
- mass spectrometry
- single cell
- small molecule
- human health
- single molecule
- bioinformatics analysis
- lymph node metastasis
- squamous cell